HomeComparePSYGF vs GBDC

PSYGF vs GBDC: Dividend Comparison 2026

PSYGF yields 1574.80% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSYGF wins by $1094146058.01M in total portfolio value
10 years
PSYGF
PSYGF
● Live price
1574.80%
Share price
$0.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1094146078.86M
Annual income
$972,648,549,767,836.50
Full PSYGF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — PSYGF vs GBDC

📍 PSYGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSYGFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSYGF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSYGF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSYGF
Annual income on $10K today (after 15% tax)
$133,858.27/yr
After 10yr DRIP, annual income (after tax)
$826,751,267,302,661.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, PSYGF beats the other by $826,751,253,319,537.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSYGF + GBDC for your $10,000?

PSYGF: 50%GBDC: 50%
100% GBDC50/50100% PSYGF
Portfolio after 10yr
$547073049.86M
Annual income
$486,324,283,109,285.20/yr
Blended yield
88.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

PSYGF
No analyst data
Altman Z
-61.3
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSYGF buys
0
GBDC buys
0
No recent congressional trades found for PSYGF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSYGFGBDC
Forward yield1574.80%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$1094146078.86M$20.85M
Annual income after 10y$972,648,549,767,836.50$16,450,733.83
Total dividends collected$1085342975.29M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: PSYGF vs GBDC ($10,000, DRIP)

YearPSYGF PortfolioPSYGF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$168,180$157,480.31$12,492$1,791.70+$155.7KPSYGF
2$2,655,195$2,475,241.96$16,527$3,160.58+$2.64MPSYGF
3$39,363,107$36,522,048.09$23,588$5,904.90+$39.34MPSYGF
4$548,134,593$506,016,068.87$37,141$11,901.65+$548.10MPSYGF
5$7,171,846,637$6,585,342,622.60$66,205$26,463.38+$7171.78MPSYGF
6$88,200,293,754$80,526,417,852.20$137,452$66,612.65+$88200.16MPSYGF
7$1,019,911,005,360$925,536,691,043.00$342,372$195,298.53+$1019910.66MPSYGF
8$11,093,656,198,301$10,002,351,422,566.60$1,053,292$686,954.33+$11093655.15MPSYGF
9$113,549,092,609,754$101,678,880,477,571.69$4,111,439$2,984,416.95+$113549088.50MPSYGF
10$1,094,146,078,860,274$972,648,549,767,836.50$20,849,974$16,450,733.83+$1094146058.01MPSYGF

PSYGF vs GBDC: Complete Analysis 2026

PSYGFStock

Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.

Full PSYGF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this PSYGF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSYGF vs SCHDPSYGF vs JEPIPSYGF vs OPSYGF vs KOPSYGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.